FindTrial
Sign In

CC312

BIOLOGICAL4 trials

Sponsors

CytoCares Inc

Conditions

Acute Lymphoblastic LeukaemiaAutoimmune Hemolytic AnemiaChronic Lymphocytic LeukemiaIIM- Idiopathic Inflammatory MyopathiesIdiopathic Inflammatory Myopathy (IIM)Non-hodgkin LymphomaPrimary Immune Thrombocytopenia (ITP)Rheumatoid Arthritis (RA)

Early Phase 1

Safety Study of CC312 in Autoimmune Disease Patients
RecruitingNCT06888960
CytoCares IncAutoimmune Hemolytic Anemia, Idiopathic Inflammatory Myopathy (IIM), Primary Immune Thrombocytopenia (ITP) +3
Start: 2024-11-08End: 2026-11-08Target: 18Updated: 2025-09-17
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
RecruitingNCT07193810
CytoCares IncIIM- Idiopathic Inflammatory Myopathies, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis
Start: 2025-09-23End: 2027-09-29Target: 6Updated: 2026-04-14

Phase 1

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
RecruitingNCT06037018
CytoCares IncAcute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
Start: 2023-08-07End: 2026-03-31Target: 44Updated: 2025-09-22
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
RecruitingNCT07177911
CytoCares IncSLE - Systemic Lupus Erythematosus
Start: 2025-09-11End: 2027-09-10Target: 32Updated: 2025-09-17

Related Papers

Abstract 5389: CC312, a novel CD19/CD3/CD28 tri-specific T cell engager, leads to rapid and deep B-cell depletion and has broad potential for development in autoimmune diseases
Cancer Research2026-04-03